leadf
logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics - Grant of Options

RNS Number : 4915Z
SkinBioTherapeutics PLC
18 September 2020
 

18 September 2020

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or "the Group")

Grant of Options
 

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that the Company has granted a total of 1,809,695 options to subscribe for new ordinary shares in the Company under the SkinBioTherapeutics Share Option Program to Professor  Catherine O'Neill, Chief Scientific Officer and Stuart Ashman, CEO both PDMRs of the Company on 3 March and 8 April 2020 respectively (the "Options").  Following an internal review of announcements it was noted that no notification had been made at the time of the relevant grants in accordance with article 19(3) of the Market Abuse Regulation and this announcement corrects this omission.

The Options for Professor O'Neill have vested with immediate effect, are exercisable at a price of 9.5p per share and will expire on 3 March 2030.

The Options for Mr Ashman can be exercised no earlier than 24 months from the date of grant and are subject to achieving performance milestones set by the Company's board which are aligned to growth in shareholder value and commercialisation of the Company's technology. The Options are exercisable at a price of 9p per share and will expire on 8 April 2030.

The following options have been granted to Directors and PDMRs:

 

 

Director

Number of options granted

 

Total number of options

 

Catherine O'Neill

 

512,334

4,404,416

 

Stuart John Ashman

 

1,297,361

5,189,444

 
 

SkinBioTherapeutics plc

Stuart J. Ashman, CEO

Doug Quinn, CFO

Tel: +44 (0) 161 468 2760

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Michael Johnson (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners

Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis

Tel: +44 (0) 20 7457 2020

[email protected]

 

 

The below makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Professor Catherine O'Neill

2

Reason for notification

 Grant of share options

a.

Position/Status

Chief Scientific Officer

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

SkinBioTherapeutics Plc

b.

LEI

213800YMQOCB23FX6I06

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Share options for ordinary shares of 1p each

 

 

ISIN: GB00BF33H870

 

b.

Nature of the transaction

 Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

9.5p

512,334

 

 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

n/a

 

 

e.

Date of the transaction

3rd March 2020

f.

Place of the transaction

Off market

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Stuart John Ashman

2

Reason for notification

 Grant of share options

a.

Position/Status

Chief Executive Officer

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

SkinBioTherapeutics Plc

b.

LEI

213800YMQOCB23FX6I06

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Share options for ordinary shares of 1p each

 

 

ISIN: GB00BF33H870

 

b.

Nature of the transaction

 Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

9.0p

1,297,361

 

 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

n/a

 

 

e.

Date of the transaction

 8th April 2020

f.

Place of the transaction

Off market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBUGDCLSBDGGI

Quick facts: SkinBioTherapeutics PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

SkinBioTherapeutics raise £4m to expand SkinBiotix technology in oral and...

Skinbiotherapeutics Plc's (LON:SBTX) Doug Quinn talks to Proactive's Katie Pilbeam on their plans for the £4m raised from existing and new institutions to fund work on new product applications. Quinn explains how they plan to expand skin biotics technology into oral and healthcare as...

on 14/10/20

6 min read